Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Non-Current Deffered Revenue (2016 - 2022)

Cytokinetics (CYTK) has disclosed Non-Current Deffered Revenue for 10 consecutive years, with $87.0 million as the latest value for Q3 2022.

  • On a quarterly basis, Non-Current Deffered Revenue changed 0.0% to $87.0 million in Q3 2022 year-over-year; TTM through Sep 2022 was $87.0 million, a 0.0% change, with the full-year FY2021 number at $87.0 million, changed 0.0% from a year prior.
  • Non-Current Deffered Revenue was $87.0 million for Q3 2022 at Cytokinetics, roughly flat from $87.0 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $87.0 million in Q4 2020 to a low of $87.0 million in Q4 2020.
  • A 3-year average of $87.0 million and a median of $87.0 million in 2020 define the central range for Non-Current Deffered Revenue.
  • Biggest YoY gain for Non-Current Deffered Revenue was 0.0% in 2021; the steepest drop was 0.0% in 2021.
  • Cytokinetics' Non-Current Deffered Revenue stood at $87.0 million in 2020, then changed by 0.0% to $87.0 million in 2021, then changed by 0.0% to $87.0 million in 2022.
  • Per Business Quant, the three most recent readings for CYTK's Non-Current Deffered Revenue are $87.0 million (Q3 2022), $87.0 million (Q1 2022), and $87.0 million (Q4 2021).